Drug Profile
ReS3 T
Alternative Names: ReS3-TLatest Information Update: 17 Jul 2023
Price :
$50
*
At a glance
- Originator reMYND
- Class Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dravet syndrome; Epilepsy
Most Recent Events
- 17 Jul 2023 ReS3 T is still in preclinical development for Epilepsy in Belgium (reMYND Pipeline, July 2023)
- 17 Jul 2023 Preclinical trials in Dravet syndrome in Belgium (unspecified route) (before July 2023) (reMYND Pipeline, July 2023)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Epilepsy in Belgium